首页> 美国卫生研究院文献>Genes >Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
【2h】

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

机译:迎接消除慢性乙型肝炎感染的挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Over 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.
机译:超过2.57亿人患有慢性乙型肝炎病毒(HBV)感染,目前尚无治愈方法。有效的预防性疫苗对现有感染没有影响。尽管存在有效抑制病毒复制的药物,但治疗通常是终生的,因此迫切需要治愈HBV感染的有限疗法。但是,即使今天可以使用这种疗法,由于慢性乙型肝炎(CHB)在全球范围内基本上未被诊断,并且迫切需要促进治疗的卫生系统,因此不可能将这些疗法运用于所有最需要的人。开发和实施有效的HBV治愈方法仍然面临着巨大挑战。尽管如此,通过目前正在临床试验中的多种新治疗药物的开发,以及通过建立致力于HBV疗法的全球新计划ICE-HBV的合作,正在取得重要的进展。与现有组织一起快速跟踪所有人可用的HBV治愈方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号